TearScience Secures $70 Million For One-Of-A-Kind Eye Device
This article was originally published in Start Up
Executive Summary
TearScience Inc. is ready to go into full-scale commercialization for a new device treatment for the most prevalent form of dry eye. In late February, the young company secured up to $70 million from HealthCare Royalty Partners to help make that happen.